Abstract
Background: Treatment strategies targeting angiogenesis have revealed promising results in preclinical studies and early clinical trials in patients with glioblastomas. Objective: This review evaluates the preclinical and clinical data for cediranib (AZD2171), a potent oral inhibitor of the VEGF receptor tyrosine kinase. Methods: We summarize both preclinical and clinical data for cediranib, with a focus on the treatment of glioblastomas. Results/conclusion: Cediranib is an effective drug in patients with glioblastoma, acting through inhibition of angiogenesis and normalization of tumor vasculature. Reduction of vasogenic brain edema is a key component of its treatment effect in this patient population. The primary side effects of cediranib include fatigue, diarrhea and hypertension.
Original language | English |
---|---|
Pages (from-to) | 1549-1557 |
Number of pages | 9 |
Journal | Expert Opinion on Investigational Drugs |
Volume | 18 |
Issue number | 10 |
DOIs | |
State | Published - Oct 2009 |
Keywords
- AZD2171
- Adverse effects
- Angiogenesis
- Brain tumors
- Cediranib
- Cerebral edema
- Glioblastoma
- Invasion
- Malignant glioma
- Stem cells